CSS VERIFIES THAT INCREASED AVAILABILITY OF MTM SERVICES FACILITATES IDENTIFICATION OF ADVERSE DRUG EFFECTS IN PSYCHIATRIC PATIENTS
BUFFALO, NY (April, 2015)—Clinical Support Services (CSS) Resident Pharmacist, Stephanie Englert, PharmD, has completed preliminary analysis of Pharmacologic Adverse Events in patients with Bipolar Disorder and Schizophrenia. Resources from Clinical Support Services Inc. clinical staff were used to conduct Comprehensive Medication Reviews (CMR) with patients currently taking psychiatric medications to assess the frequency of adverse drug events. The research found that 93% of patients experienced at least one ADE and 87% experienced two or more ADE’s.
The Center for Medicare and Medicaid Services requires a Medication Therapy Management program as a component of the Medicare Part D benefit. This includes a Comprehensive Medication Review (CMR) in which a clinician engages the patient in a review of their medication regiment providing an opportunity to assess medication use and adverse events.
Of the research, CSS President James Notaro, PhD, PharmD, says, “There may be a case to be made for conducting Medication Therapy Management (MTM) in non-Part D populations who would be likely to experience a similar level of adverse effects. Moreover, this type of work illustrates how Medication Therapy Management can play a key component in a population health effort.”
Dr. Englert presented her findings at this year’s AMCP Annual Meeting and Expo in San Diego, CA on April 9th, 2015.